<DOC>
	<DOC>NCT01213836</DOC>
	<brief_summary>This will be a phase IV 20 -32 day prospective, double blind, double-dummy, randomised crossover study that will evaluate the effect of quetiapine XR and quetiapine IR on cognitive performance in patients with schizophrenia stabilized on a single antipsychotic medication.</brief_summary>
	<brief_title>Compare the Effect on Cognitive Functioning of Two Formulations of Seroquel, Seroquel XR and IR in Patients With Stable Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Provision of written informed consent prior to any study specific procedures Documented clinical diagnosis of schizophrenia, paranoid type, for at least 2 years before randomisation meeting the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSMIV, American Psychiatric Association 2000) criteria of schizophrenia (DSMIV codes 295.3) confirmed by MINI version 5.0 Outpatient status at enrolment Dose of quetiapine IR or quetiapine XR unchanged during the last 56 days before randomisation Diagnosis of any DSMIV Axis I disorder other than those included in inclusion criteria above within 6 months before randomisation (e.g., alcohol dependence or psychoactive substance dependence not in full remission, concurrent organic mental disorder, or mental retardation [axis II diagnosis]) of a degree that may interfere with the patient's ability to cooperate. Previous stable use of high dosage of benzodiazepines during one year or more Significant neurological medical history (complicated head trauma as judged by the investigator, epilepsy, meningoencephalitis) Use of the following medication: other antipsychotic drug than quetiapine within 28 days prior to randomisation a depot antipsychotic injection within two dosing intervals (for the depot) before randomisation (Visit 2) other psychoactive drugs within 14 days prior to randomisation (hypnotic or anxiolytic drugs, other than those allowed) Use of concomitant therapy likely to affect cognition, Medication prohibited 28 days prior to randomisation: benzodiazepines, amphetamines, reboxitin, atomoxinetine, buspiron, donepezil, duloxetine, galantamine, ginko biloba, memantine, methylphenidate, modafinil, rivastigmine, tacrine, smoking cessation therapy varencicline and any dosage form of nicotine replacement therapy. Medication prohibited 14 days prior to randomisation: irreversible monoamine oxidase inhibitors (MAOI), tricyclic antidepressants (TCA), biperiden, antoicholinergic agents (even if the indications are extra pyramidal symptoms or urinary symptoms)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Stable schizophrenia</keyword>
	<keyword>cognitive functioning</keyword>
</DOC>